Comparative Pharmacology
Head-to-head clinical analysis: ANTIVERT versus CLOPRA YELLOW.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTIVERT versus CLOPRA YELLOW.
ANTIVERT vs CLOPRA-"YELLOW"
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antivert (meclizine) is a piperazine H1 histamine receptor antagonist with central anticholinergic and sedative properties. It suppresses the chemoreceptor trigger zone and labyrinthine apparatus, reducing vestibular stimulation and vertigo.
Clopra (metoclopramide) is a dopamine D2 receptor antagonist and, at higher doses, a serotonin 5-HT4 receptor agonist, which enhances gastrointestinal motility and accelerates gastric emptying. It also has central antiemetic effects via D2 blockade in the chemoreceptor trigger zone.
25-100 mg orally daily in divided doses 2-4 times daily; maximum 400 mg/day.
Adult: 25-50 mg orally 3-4 times daily; maximum 200 mg/day. For severe pain: 50-100 mg intramuscularly every 4-6 hours; maximum 300 mg/day.
None Documented
None Documented
Terminal elimination half-life is 35–50 hours in adults; prolonged in renal impairment.
8-12 hours in normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal (urine) as unchanged drug and metabolites; biliary excretion is minimal. Approximately 80% excreted unchanged in urine.
Renal: 70% unchanged, Biliary/Fecal: 20% as metabolites, 10% other
Category C
Category C
Antiemetic
Antiemetic/Prokinetic Agent